Codexis and the CDMO Nitto Denko Avecia have announced that they have entered into an evaluation agreement.
Under the terms of the agreement, Nitto Denko Avecia will evaluate Codexis’ ECO Synthesis Manufacturing Platform.
The collaboration will pave the way for licencing discussions and broader adoption of the ECO Synthesis platform, which replaces traditional solid-phase oligonucleotide synthesis with a flexible, enzyme-catalysed approach built to scale.
“We are excited to partner with Nitto Denko Avecia, a recognised leader in therapeutic oligonucleotide manufacturing,” said Stephen Dilly, Chair and CEO at Codexis.
“This collaboration represents a significant milestone toward expanding the reach of our ECO Synthesis Manufacturing Platform, through best-in-class CDMO collaborations.”
“At Nitto Denko Avecia, we are constantly looking to the future of oligonucleotide manufacturing,” said Tammy Cooper, President at Nitto Denko Avecia.
“Exploring Codexis’ ECO Synthesis Manufacturing Platform reflects our commitment to pioneering next-generation technologies that can redefine scalability, sustainability and innovation in therapeutic development."
"This collaboration aligns with our mission to deliver high-quality therapeutics to our partners and patients worldwide.”
By combining Codexis’ innovative ECO Synthesis Manufacturing Platform with Nitto Denko Avecia’s expertise in manufacturing oligonucleotide therapeutics at scale, this collaboration marks a pivotal step toward advancing scalable and sustainable therapeutic siRNA manufacturing.